Smart targeting of EGFR in lung cancer

Pharmacogenomics

Volumn 11, Issue 6, 2010, Pages 743-744

  Kermorgant, Stéphanie ^a   Nevo, Jonna ^b   Ivaska, Johanna ^b,c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; NERATINIB; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR;

BINDING SITE; BREAST CANCER; CANCER PROGNOSIS; COMPETITIVE INHIBITION; DRUG EFFICACY; DRUG TARGETING; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; LUNG NON SMALL CELL CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; PROTO ONCOGENE; SHORT SURVEY; TREATMENT OUTCOME;

EID: 77952943375     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.78     Document Type: Short Survey

References (10)

1. Sharma SV, Bell DW, Settleman J et al.: Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer. 7(3), 169-181 (2007).
2. Bunn PA Jr, Helfrich B, Soriano AF et al.: Expression of her-2/neu in human lung cancer cell lines by immunohistochemistry and fuorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin. Cancer Res. 7(10), 3239-3250 (2001).
3. Lynch TJ, Bell DW, Sordella R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to geftinib. N. Engl. J. Med. 350(21), 2129-2139 (2004).
4. Paez JG, Janne PA, Lee JC et al.: EGFR mutations in lung cancer: correlation with clinical response to geftinib therapy. Science 304(5676), 1497-1500 (2004).
5. Pao W, Miller V, Zakowski M et al.: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to geftinib and erlotinib. Proc. Natl Acad. Sci. USA 101(36), 13306-13311 (2004).
6. Riely GJ, Pao W, Pham D et al.: Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with geftinib or erlotinib. Clin. Cancer Res. 12(3 Pt 1), 839-844 (2006).
7. Kobayashi S, Boggon TJ, Dayaram T et al.: EGFR mutation and resistance of non-small-cell lung cancer to geftinib. N. Engl. J. Med. 352(8), 786-792 (2005). (Pubitemid 40271173)
8. Balak MN, Gong Y, Riely GJ et al.: Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin. Cancer Res. 12(21), 6494-6501 (2006).
9. Engelman JA, Zejnullahu K, Mitsudomi T et al.: MET amplifcation leads to geftinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827), 1039-1043 (2007).
10. Yano S, Wang W, Li Q et al.: Hepatocyte growth factor induces geftinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 68(22), 9479-9487 (2008).